EISAI SUBMITS NEW APPLICATION IN EUROPE FOR IN-HOUSE DEVELOPED ANTICANCER AGENT LENVATINIB SEEKING APPROVAL FOR INDICATION COVERING RENAL CELL CARCINOMA

APPLICATION BASED ON RESULTS OF PHASE II CLINICAL STUDY

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate (generic name, “lenvatinib”) for use in the treatment of advanced or metastatic renal cell carcinoma. As a new medicine that is

[Notes to editors]

1. About lenvatinib mesylate (generic name, lenvatinib)

Lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor